Research and development
pipeline

Our research and development pipeline covers some of the therapeutic areas with the highest need for care.

Ophthalmology

NERVE GROWTH FACTOR (NGF)

Discovered in the 1950s by Rita Levi Montalcini, the Nerve Growth Factor (NGF) is a neurotrophin - a family of proteins that can play a key role in regulating the survival, development and function of neurons, both at a central and peripheral level.

It was the first neurotrophic factor to be identified and purified. Over the last fifty years, its role in neuronal development and its biological activity on neural tissue has become more and more significant.

The potential of the NGF in ophthalmology has been studied in depth by researchers at Anabasis, an Italian research company that has since merged with Dompé, subsequently developing an NGF ophthalmic formulation for the preclinical and clinical stages of various ophthalmic disorders.

RHNGF
DRY EYE SYNDROME

  • DISCOVERY

  • PRECLINICAL

  • PHASE I

  • PHASE II

  • PHASE III

RHNGF
GLAUCOMA

  • DISCOVERY

  • PRECLINICAL

  • PHASE I

  • PHASE II

  • PHASE III

Diabetology

LADARIXIN

Ladarixin is a drug resulting from Dompé’s research - an inhibitor of IL-8, a molecule involved in the inflammatory processes leading to the progressive autoimmune destruction of the cells of the islets of Langerhans in type 1 diabetes.

Currently being tested in phase II clinical trials, the drug is designed to innovatively counteract the inflammatory reactions in the early stage of type 1 diabetes.

The goal of a treatment with Ladarixin is to limit the phenomena resulting from the body’s ‘wrong’ immune response and leading to the production of active antibodies and T cells against pancreatic islet cells and hence to the onset of type 1 diabetes.

LADARIXIN
TYPE 1 DIABETES ONSET

  • DISCOVERY

  • PRECLINICAL

  • PHASE I

  • PHASE II

  • PHASE III

Pain

REPARIXIN

Identified by Dompé laboratories in Italy and currently at an advanced stage (phase II) of clinical development, Reparixin is an inhibitor of CXCR1 and CXCR2 receptors.

It is the first of a new class of low-molecular-weight inhibitors that can selectively modulate the receptor activity through an allosteric mechanism of action.

Reparixin is activated by interleukin-8 (IL-8), a key chemotactic factor in the inflammatory reaction that immediately follows pancreatic islet transplantation (either autologous or allogeneic). It can ‘recall’ and facilitate the action of specific white blood cells that may damage the transplanted islets.

Because of its significant innovation and potential effective response to the yet unmet need of reducing the risk of rejection in pancreatic islet transplantation (an extremely rare condition), Reparixin has been classified as an orphan drug by the EMA in Europe and the FDA in the US.

REPARIXIN
Breast Cancer

  • DISCOVERY

  • PRECLINICAL

  • PHASE I

  • PHASE II

  • PHASE III

Dompé Farmaceutici S.p.A. Single shareholder company / Share capital € 50.000.000,00
REA MI 289519 - A registered company in Milan, Italy / Tax code and VAT number IT00791570153